CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Celularity Inc
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Oct 20, 2026
$1.16−0.09 (-7.20%)
Close on Oct 19, 2026
- Market cap
- $35.15M
- P/E (TTM)
- –
- Dividend yield
- –
Celularity statistics
Financials through Mar 31, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Celularity | Industry median |
|---|---|---|
| Market Cap | $37.64M | $197.05M |
| Enterprise Value | $37.27M | $106.56M |
| PS Ratio | 1.98 | 3.93 |
Enterprise value
| Measure | Celularity | Industry median |
|---|---|---|
| EV / Sales | 1.96 | 2.69 |
Income (trailing twelve months)
| Measure | Celularity | Industry median |
|---|---|---|
| Revenue | $18.97M | $57.94M |
| Gross Profit | $998.00K | $90.47M |
| Operating Income | -$60.96M | -$21.44M |
| Pretax Income | -$71.09M | -$14.45M |
| Net Income | -$71.09M | -$22.46M |
| EBITDA | -$53.90M | -$16.91M |
| EPS (Diluted) | -$2.74 | -$0.83 |
Margins
| Measure | Celularity | Industry median |
|---|---|---|
| Gross Margin | 5.26% | 52.3% |
| Operating Margin | -321.3% | -44.5% |
| Pretax Margin | -374.7% | -13.0% |
| Profit Margin | -374.7% | -39.2% |
| EBITDA Margin | -284.1% | -31.3% |
Returns
| Measure | Celularity | Industry median |
|---|---|---|
| Return on Assets (ROA) | -62.3% | -41.0% |
| Return on Capital Employed (ROCE) | -210.9% | -37.8% |
Growth
| Measure | Celularity | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -62.8% | 6.01% |
| Revenue Growth (3Y CAGR) | 13.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 13.2% | 6.42% |
Balance sheet
| Measure | Celularity | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $368.00K | $62.42M |
| Net Cash (Debt) | $368.00K | $15.68M |
| Net Cash Per Share | $0.01 | $0.65 |
| Equity (Book Value) | -$35.26M | $48.79M |
| Book Value Per Share | -$1.09 | $1.36 |
| Tangible Book Value | -$50.00M | $23.06M |
| Working Capital | -$64.28M | $75.77M |
Financial position
| Measure | Celularity | Industry median |
|---|---|---|
| Current Ratio | 0.09 | 3.30 |
| Quick Ratio | 0.07 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Celularity | Industry median |
|---|---|---|
| Operating Cash Flow | -$8.81M | -$12.35M |
Efficiency
| Measure | Celularity | Industry median |
|---|---|---|
| Asset Turnover | 0.17 | 0.38 |
| Inventory Turnover | 5.39 | 2.67 |
| Revenue Per Employee | $164.96K | $398.96K |
| Profits Per Employee | -$618.16K | -$732.08K |
| Employee Count | 115 | 73 |
Dividends and yields
| Measure | Celularity | Industry median |
|---|---|---|
| Earnings Yield | -188.9% | -21.2% |
Shares
| Measure | Celularity | Industry median |
|---|---|---|
| Shares Outstanding | 32,449,800 | 59,128,900 |
| Shares Change (YoY) | 21.7% | 11.1% |
| Shares Change (QoQ) | 1.19% | 0.54% |
| Shares Held by Institutions | 6.78% | 59.4% |
Scores
| Measure | Celularity | Industry median |
|---|---|---|
| Altman Z-Score | -16.38 | 0.10 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Celularity's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.